81 FR 81150 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 222 (November 17, 2016)

Page Range		81150-81150
FR Document		2016-27677

Federal Register, Volume 81 Issue 222 (Thursday, November 17, 2016)

[Federal Register Volume 81, Number 222 (Thursday, November 17, 2016)]
[Notices]
[Page 81150]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-27677]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Phase II In-person Interview: NIDA Avant-Garde Award 
Program for HIV/AIDS Research (DP1).
    Date: December 12, 2016.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy 
Chase, MD 20815.
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Affairs, National Institute on Drug Abuse, 
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 
4238, MSC 9550, Bethesda, MD 20892, (301) 827-5820, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Laboratory and Diagnostic Tools to Advance 
Microbiome-Brain Research (R41/R42/R43/R44).
    Date: December 13, 2016.
    Time: 10:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, 
Bethesda, MD 20814.
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, 301-827-5819, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Multi-site Clinical Trials SEP II.
    Date: December 14, 2016.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., 
Room 4245, Rockville, MD 20852, (301) 827-5817, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: November 14, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-27677 Filed 11-16-16; 8:45 am]
 BILLING CODE 4140-01-P

81150 Federal Register / Vol. 81, No. 222 / Thursday, November 17, 2016 / Notices

Emphasis Panel; NIAID Resource-Related Laboratory and Diagnostic Tools to Advance Center, National Cancer Institute, 9609
Research Projects (R24). Microbiome-Brain Research (R41/R42/R43/ Medical Center Drive, Mail Stop 9702,
Date: December 12, 2016. R44). Rockville, MD 20850–9702.
Time: 2:00 p.m. to 3:00 p.m. Date: December 13, 2016.
Agenda: To review and evaluate grant Time: 10:00 a.m. to 3:00 p.m. FOR FURTHER INFORMATION CONTACT:
applications. Agenda: To review and evaluate grant Information on licensing and co-
Place: National Institutes of Health, 5601 applications. development research collaborations,
Fishers Lane, Room 3E73, Rockville, MD Place: Hilton Garden Inn Bethesda, 7301 and copies of the U.S. patent
20892 (Telephone Conference Call). Waverly Street, Bethesda, MD 20814. applications listed below may be
Contact Person: Audrey O. Lau, Ph.D., Contact Person: Gerald L. McLaughlin, obtained by contacting: Attn. Invention
Scientific Review Officer, Scientific Review Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Development and Marketing Unit,
Program, DEA/NIAID/NIH/DHHS, 5601
Fishers Lane, MSC–9823, Rockville, MD Institute on Drug Abuse, NIH, DHHS, 6001 Technology Transfer Center, National
20852, 240–669–2081, audrey.lau@nih.gov. Executive Blvd., Room 4238, MSC 9550, Cancer Institute, 9609 Medical Center
(Catalogue of Federal Domestic Assistance Bethesda, MD 20892–9550, 301–827–5819, Drive, Mail Stop 9702, Rockville, MD,
Program Nos. 93.855, Allergy, Immunology, gm145a@nih.gov. 20850–9702, Tel. 240–276–5515 or
and Transplantation Research; 93.856, Name of Committee: National Institute on email ncitechtransfer@mail.nih.gov. A
Microbiology and Infectious Diseases Drug Abuse Special Emphasis Panel; Multi- signed Confidential Disclosure
Research, National Institutes of Health, HHS) site Clinical Trials SEP II. Agreement may be required to receive
Date: December 14, 2016. copies of the patent applications.
Dated: November 14, 2016. Time: 1:00 p.m. to 3:00 p.m.
Natasha M. Copeland, Agenda: To review and evaluate grant SUPPLEMENTARY INFORMATION:
Program Analyst, Office of Federal Advisory applications. Technology description follows.
Committee Policy. Place: National Institutes of Health, Title of invention: Gene Signature
Neuroscience Center, 6001 Executive Predictive of Hepatocellular Carcinoma
[FR Doc. 2016–27675 Filed 11–16–16; 8:45 am]
Boulevard, Rockville, MD 20852 (Telephone Response to Transcatheter Arterial
BILLING CODE 4140–01–P Conference Call). Chemoembolization (TACE).
Contact Person: Susan O. McGuire, Ph.D.,
Keywords: Diagnostic, Biomarker,
Scientific Review Officer, Office of
DEPARTMENT OF HEALTH AND Extramural Affairs, National Institute on Prognostic, Hepatocellular Carcinoma,
HUMAN SERVICES Drug Abuse, National Institutes of Health, Patient Stratification, TACE, HCC.
DHHS, 6001 Executive Blvd., Room 4245, Description of Technology:
National Institutes of Health Rockville, MD 20852, (301) 827–5817, Hepatocellular Carcinoma (HCC) is one
mcguireso@mail.nih.gov. of the most common cancers worldwide
National Institute on Drug Abuse; (Catalogue of Federal Domestic Assistance with largely unfavorable outcomes due
Notice of Closed Meetings Program Nos.: 93.279, Drug Abuse and to a lack of effective treatment options
Addiction Research Programs, National for patients in the later state of disease.
Pursuant to section 10(d) of the Institutes of Health, HHS)
Federal Advisory Committee Act, as The gold standard of care for HCC
Dated: November 14, 2016. patients with intermediate to locally
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
Natasha M. Copeland, advanced tumors is transcatheter
The meetings will be closed to the Program Analyst, Office of Federal Advisory arterial chemoembolization (TACE), a
public in accordance with the Committee Policy. procedure whereby the tumor is targeted
provisions set forth in sections [FR Doc. 2016–27677 Filed 11–16–16; 8:45 am] both with local chemotherapy and
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., BILLING CODE 4140–01–P restriction of local blood supply. TACE
as amended. The grant applications and procedures are often not effective,
the discussions could disclose however, and a need exists to identify
confidential trade secrets or commercial DEPARTMENT OF HEALTH AND patients that will respond to TACE.
property such as patentable material, HUMAN SERVICES Scientists in NCI’s Laboratory of
and personal information concerning Human Carcinogenesis have identified a
National Institutes of Health 14-gene signature that is predictive of
individuals associated with the grant
applications, the disclosure of which response to TACE. The ‘‘TACE
Government-Owned Inventions; Navigator Gene Signature Assay,’’ based
would constitute a clearly unwarranted Availability for Licensing and/or Co-
invasion of personal privacy. on a Nanostring Technologies platform,
Development is useful in identifying those HCC
Name of Committee: National Institute on patients, prior to treatment, who will
AGENCY: National Institutes of Health.
Drug Abuse Special Emphasis Panel; Phase II
HHS. respond to and have the greatest
In-person Interview: NIDA Avant-Garde
Award Program for HIV/AIDS Research ACTION: Notice. survival benefit following TACE. The
(DP1). signature can also identify patients who
Date: December 12, 2016. SUMMARY: The invention listed below is need additional/alternative therapeutic
Time: 8:00 a.m. to 5:00 p.m. owned by an agency of the U.S. modalities.
Agenda: To review and evaluate grant Government and is available for This invention is owned by an agency
applications. licensing and/or co-development in the of the U.S. Government and is available
Place: Courtyard by Marriott, 5520 U.S. to achieve expeditious for licensing and/or co-development in
Wisconsin Avenue, Chevy Chase, MD 20815. commercialization of results of the U.S., in accordance with 35 U.S.C.
asabaliauskas on DSK3SPTVN1PROD with NOTICES

Contact Person: Hiromi Ono, Ph.D., federally-funded research and 209 and 37 CFR part 404, to achieve
Scientific Review Officer, Office of development. Foreign patent
Extramural Affairs, National Institute on
expeditious commercialization of
Drug Abuse, National Institutes of Health,
applications are filed on selected results of federally-funded research and
DHHS, 6001 Executive Boulevard, Room inventions to extend market coverage development. Foreign patent
4238, MSC 9550, Bethesda, MD 20892, (301) for companies and may also be available applications are filed on selected
827–5820, hiromi.ono@nih.gov. for licensing and/or co-development. inventions to extend market coverage
Name of Committee: National Institute on ADDRESSES: Invention Development and for companies and may also be available
Drug Abuse Special Emphasis Panel; Marketing Unit, Technology Transfer for licensing and/or co-development.

VerDate Sep<11>2014 21:24 Nov 16, 2016 Jkt 241001 PO 00000 Frm 00098 Fmt 4703 Sfmt 4703 E:\FR\FM\17NON1.SGM 17NON1

Document Created: 2016-11-17 03:00:26
Document Modified: 2016-11-17 03:00:26

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		December 12, 2016.
FR Citation		81 FR 81150

81 FR 81150 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 81, Issue 222 (November 17, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health